Publications in collaboration with researchers from University of Alberta (25)

2022

  1. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

    The Lancet. Haematology, Vol. 9, Núm. 6, pp. e403-e414

  2. Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL

    Leukemia and Lymphoma, Vol. 63, Núm. 9, pp. 2063-2073

2021

  1. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

    British Journal of Haematology

  2. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

    American Journal of Hematology, Vol. 96, Núm. 6, pp. 708-718

  3. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

    Journal of Hematology and Oncology

  4. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

    American Journal of Hematology, Vol. 96, Núm. 9, pp. 1120-1130

  5. Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19

    New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802

2020

  1. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    Blood Cancer Journal, Vol. 10, Núm. 9

  2. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573

2019

  1. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

    European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973

  2. Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data

    The Lancet Neurology, Vol. 18, Núm. 1, pp. 46-55

2017

  1. Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis

    American Heart Journal, Vol. 193, pp. 46-54

  2. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

    British Journal of Haematology, Vol. 178, Núm. 6, pp. 896-905

  3. Impact of prior therapy on the efficacy and safety of oral ixazomiblenalidomide-dexamethasone vs. Placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

    Haematologica, Vol. 102, Núm. 10, pp. 1767-1775

2016

  1. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis

    Transplant International, Vol. 29, Núm. 11, pp. 1216-1225

  2. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

  3. Tracking post-infectious fatigue in clinic using routine Lab tests

    BMC Pediatrics, Vol. 16, Núm. 1

2015

  1. Consistency of benefit from an early invasive strategy after fibrinolysis: A patient-level meta-analysis

    Heart, Vol. 101, Núm. 19, pp. 1554-1561

  2. Elotuzumab therapy for relapsed or refractory multiple myeloma

    New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631

  3. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report

    Blood, Vol. 125, Núm. 13, pp. 2068-2074